We are Traded On
NASDAQ: ELAB
2020
About Us
PMGC currently manages and operates a diverse portfolio of three wholly owned subsidiaries:
Northstrive Biosciences Inc. a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit Northstivebio.com.
PMGC Research Inc. is a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation.
PMGC Capital LLC. A multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Our mission is to identify and seize high-potential opportunities, delivering sustainable growth and maximizing returns on capital.
At PMGC, we are dedicated to driving growth and enhancing shareholder value by strategically developing and acquiring high-potential companies and assets.
Formation of Elevai Labs Inc.
Elevai Labs was incorporated in Delaware, establishing itself as a physician-dispensed skincare company, focused on modernizing aesthetic skincare with innovative stem cell-derived Elevai Exosomes™ products.
2021
Stock Transfer Agreement with Reactive Medical Labs Inc.
Elevai Labs entered into a stock transfer agreement with Reactive Medical Labs Inc., acquiring all assets and liabilities, and establishing a foothold in Canada for research and development through its subsidiary, Elevai Research Inc. (formerly Reactive Medical Inc.).
2022
Launch of Elevai Skincare Products
Elevai Labs began commercializing its E-Series™ products, targeting the medical aesthetics industry through a business-to-business model, distributing its exosome-infused skincare solutions for post-procedure care and ongoing aftercare.
2023
Q4
Elevai Labs, Inc. Nasdaq Initial Public Offering (IPO)
On November 20, 2023, Elevai Labs priced its IPO, raising $6 million through the sale of 1.5 million shares of common stock at $4.00 per share. The company began trading on the Nasdaq Capital Market under the ticker symbol "ELAB."
2024
Q2
Initiation of Restructuring with the Launch of two wholly owned subsidiaries Elevai Biosciences, Inc. and Elevai Skincare, Inc.
Elevai Biosciences focused on biopharmaceutical innovations, including obesity-targeting assets EL-22 and EL-32. Elevai Skincare became dedicated to commercializing Elevai's exosome skincare technologies, with an emphasis on scaling and increasing market penetration in the medical skincare industry.
Q4
Parent company Elevai Labs Inc. leadership transition and corporate name change to PMGC Holdings Inc. Announces Pricing of $8.0 Million Public Offering
2025
Q1
The sale of Elevai Skincare to Carmell Corporation
Sold Elevai Skincare to Carmell Corporation, strengthening PMGC's balance sheet, maximizing immediate financial benefit while securing future upside through structured royalties and milestone payments.Note: PMGC Holdings (formerly known as Elevai Labs)
Expands Investment & M&A Efforts, Actively Seeking Acquisitions